Neurogene (NGNE) Change in Accured Expenses (2013 - 2026)

Neurogene has reported Change in Accured Expenses for 14 years, with the latest figure at $359000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 116.3% year-over-year to $359000.0; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 4457.73% YoY), and the FY2025 full-year result was $1.7 million, up 160.04% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $359000.0, down from $1.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.6 million in Q3 2024, with the low at -$4.9 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$206882.4 across 5 years, with a median of $359000.0 in 2026.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 260.08% — and 2025, when it soared 949.28%.
• Neurogene's Change in Accured Expenses stood at -$1.0 million in 2022, then slumped by 260.08% to -$3.7 million in 2023, then soared by 79.71% to -$743000.0 in 2024, then jumped by 279.14% to $1.3 million in 2025, then tumbled by 73.03% to $359000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $359000.0 (Q1 2026), $1.3 million (Q4 2025), and $365000.0 (Q3 2025), per Business Quant data.